BMS wins dual immunotherapy-first approvals in classical Hodgkin Lymphoma

CE2026-03-23T12:16:00

hodgkins lymphoma light micrograph image

Source:

Expanded EU and US approvals for Bristol Myers Squibb’s Opdivo (nivolumab) position combination therapy as frontline option for the common blood cancer.

Biologic Opdivo (nivolumab) is now authorised as a combination therapy for two new classical Hodgkin Lymphoma indications.

Firstly, the FDA has authorised the monoclonal antibody alongside doxorubicin, vinblastine and dacarbazine (AVD) in individuals 12 years old and over with previously untreated, Stage III or IV cHL. It represents the first immunotherapy

Already a member? Sign-in

Unlock

Driving innovation in pharma manufacturing

European Pharmaceutical Review delivers authoritative insights, cutting-edge innovations, and expert perspectives that not only inform decisions but drive measurable progress across quality, compliance, and operational excellence.

Become a member to continue reading

By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:

Unlimited access to industry intelligence that can make a difference to your business
A weekly newsletter keeping the most vital information at the front of your thinking
Exclusive invitations to powerful webinars and events featuring high profile experts
Access to deep-dive reports and analysis that reveal exciting new opportunities for business growth and transformation

Become a member